SCHEMBL10288306

SCHEMBL10288306

c1ccc2cc(Cc3cc(N4CCOCC4)sc3-c3nnn[nH]3)ccc2c1

nearest known ligand 0.40

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
PDE10A Q9Y233 1/20 0.37
PRKDC P78527 3/20 0.33
TPH1 P17752 1/20 0.33
P2RY12 Q9H244 1/20 0.33
CETP P11597 1/20 0.33
ALOX5 P09917 1/20 0.33
SIGMAR1 Q99720 1/20 0.32
CYP2D6 P10635 1/20 0.32
NFKB1 P19838 1/20 0.32
TAAR1 Q96RJ0 1/20 0.32
KMT2A Q03164 1/20 0.32
HTR6 P50406 1/20 0.32
PIK3CD O00329 1/20 0.32
PIK3CA P42336 1/20 0.32
PIK3CG P48736 1/20 0.32
AR P10275 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL626480 0.82 NPC1 (0.37) PDE10APRKDCCETPPIK3CDPIK3CA
SCHEMBL10288142 0.80 PDE10A (0.36) PDE10APRKDCTPH1CETPSIGMAR1
SCHEMBL627366 0.78 PIK3CA (0.40) PIK3CDPIK3CAPIK3CG
SCHEMBL10298513 0.78 PDE10A (0.34) PDE10APRKDCCETP
SCHEMBL16849917 0.72 PIK3CB (0.41) PDE10APRKDCTPH1P2RY12ALOX5
SCHEMBL16850491 0.67 PDE10A (0.41) PDE10ACETPPIK3CDPIK3CAPIK3CG
SCHEMBL10298533 0.66 KDM4E (0.32) PIK3CA
SCHEMBL949313 0.66 MPO (0.42) PDE10AALOX5CYP2D6NFKB1TAAR1
SCHEMBL1247974 0.65 CYP2D6 (0.46) PDE10AALOX5CYP2D6NFKB1TAAR1
SCHEMBL15925455 0.65 AR (0.52) PDE10AP2RY12CETPPIK3CDPIK3CA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20150175563-A1 HETEROARYLS AND USES THEREOF MILLENNIUM PHARM INC (US) 2015-06-25 US disclosed
US-20150175593-A1 HETEROARYLS AND USES THEREOF MILLENNIUM PHARM INC (US) 2015-06-25 US disclosed
US-8796271-B2 Heteroaryls and uses thereof MILLENNIUM PHARMACEUTICALS, INC. (US) 2014-08-05 US disclosed
US-8796268-B2 Heteroaryls and uses thereof MILLENNIUM PHARMACEUTICALS, INC. (US) 2014-08-05 US disclosed
US-8796268-B2 Heteroaryls and uses thereof MILLENNIUM PHARMACEUTICALS, INC. (US) 2014-08-05 US disclosed
US-20120178723-A1 HETEROARYLS AND USES THEREOF MILLENNIUM PHARMACEUTICALS, INC. (US) 2012-07-12 US disclosed
US-20120172345-A1 HETEROARYLS AND USES THEREOF MILLENNIUM PHARMACEUTICALS, INC. (US) 2012-07-05 US disclosed
US-20120172345-A1 HETEROARYLS AND USES THEREOF MILLENNIUM PHARMACEUTICALS, INC. (US) 2012-07-05 US disclosed
WO-2012021696-A1 HETEROARYLS AND USES THEREOF MILLENNIUM PHARMACEUTICALS, INC. (US) 2012-02-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120172345-A1 HETEROARYLS AND USES THEREOF PIK3R1, PIK3R2, PIK3R3 PDE10A 2609/4885PRKDC 3512/4885TPH1 908/4885
US-20150175563-A1 HETEROARYLS AND USES THEREOF PIK3R1, PIK3R2, PIK3R3 PDE10A 2609/4885PRKDC 3512/4885TPH1 908/4885
US-20120178723-A1 HETEROARYLS AND USES THEREOF PIK3R1, PIK3R2, PIK3R3 PDE10A 2341/4885PRKDC 3849/4885TPH1 926/4885
US-20150175593-A1 HETEROARYLS AND USES THEREOF PIK3R1, PIK3R2, PIK3R3 PDE10A 2341/4885PRKDC 3849/4885TPH1 926/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.